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ABSTRACT
Aims: To summarise evidence on the frequency and predictors of healthcare utilisation among people 
who use illicit drugs.
Design: Systematic search of MEDLINE, EMBASE and PsychINFO for observational studies 
reporting healthcare utilisation published between 1 January 2000 and 3 December 2018. We 
conducted narrative synthesis and meta-analysis following a registered protocol (identifier: 
CRD42017076525). 
Setting and participants: People who use heroin, powder cocaine, crack cocaine, methamphetamine, 
amphetamine, ecstasy/MDMA, cannabis, hallucinogens, or novel psychoactive substances; have a 
diagnosis of ‘substance use disorder’; or use drug treatment services.
Measurements: Primary outcomes were the cumulative incidence (risk) and rate of care episodes in 
three settings: primary care, hospital admissions (inpatient) and emergency department (ED).
Findings: 92 studies were included; 84% from North America and Australia. Most studies focused on 
people using heroin, methamphetamine or crack cocaine, or who had a diagnosis of drug dependence. 
We were able to conduct meta-analysis of rates across 25 studies reporting ED episodes and 25 
reporting hospital admissions, finding pooled rates of 151 (95% CI 114-201) and 41 (95% CI 30-57) 
per 100 person-years respectively; on average 4.8 and 7.1 times the general population. Heterogeneity 
was very high and was not explained by drugs used, country of study, recruitment setting or 
demographic characteristics. Predictors of healthcare utilisation were consistent across studies and 
included unstable housing, drug injection and mental health problems. Opioid substitution therapy 
was consistently associated with reduced ED presentation and hospital admission. There was minimal 
research on healthcare utilisation by people using ecstasy/MDMA, powder cocaine, hallucinogens or 
novel psychoactive substances.
Conclusions: People who use illicit drugs are admitted to ED or hospital several times more often 
than the general population. Further research is needed to understand the quality of healthcare for this 
group, and healthcare provision in non-acute settings.
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INTRODUCTION
Illicit use of drugs is associated with health, social and economic problems. People who are dependent 
on illicit drugs generally have poor health outcomes, with cohort studies finding mortality rates of up 
to 15 times the general population, though this varies widely by population and setting [1,2]. As well 
as overdose, there is excess risk of cancers, cardiovascular, respiratory and liver diseases [3,4]. Excess 
disease may be due to both the direct effects of illicit drugs and accompanying life circumstances. For 
instance, people who use illicit drugs are vulnerable to homelessness, imprisonment, and other forms 
of social exclusion [5], and have high rates of tobacco smoking and harmful alcohol consumption. 
There are diverse subgroups of people who use drugs, and people who smoke cannabis or use illicit 
drugs occasionally may have better health outcomes than people who use drugs such as heroin, crack 
cocaine and methamphetamine [7,8].
Despite the high need for healthcare, qualitative research has identified multiple barriers for people 
who use illicit drugs. Health professionals may have negative perceptions of patients who use illicit 
drugs, including poor motivation, seeking prescriptions for non-medical purposes, and violent 
behaviour; and may feel they lack training and skills to address the needs of this group [9]. Patients 
report that staff have stigmatising attitudes and that there are barriers to attending appointments, such 
as inflexible timeslots and transport costs [10]. People who use drugs may delay treatment due to 
normalisation of pain, fear of stigma in services, and concern about inadequate opioid substitution and 
pain control when admitted to hospital [11]. These barriers mean that symptoms may not be 
addressed, leading to presentation late in the course of a disease and use of emergency care. People 
who use illicit drugs face distinct challenges to healthcare access due to criminalisation and related 
social exclusion. We have therefore chosen to focus on this group rather than include people who use 
alcohol, tobacco, or other legal drugs.
Studies of patients visiting emergency departments (ED) have found that 10%-20% report recent use 
of illicit drugs [12–14]; much higher than the general population, and diagnoses of drug dependence 
are common among frequent ED users [15,16]. Frequent ED users are particularly likely to use drugs 
[17]. Such observations have led to a perception that people who use drugs are dependent on ED 
services, but there is limited population-based research into the frequency and patterns of healthcare 
utilisation in this group. We aimed to (1) describe the frequencies of healthcare utilisation reported in 
observational studies of people who use illicit drugs and calculate pooled averages; (2) compare the 
frequency of healthcare utilisation to the general population; and (3) summarise evidence on the 
predictors and causes of healthcare utilisation.
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METHODS
Review protocol
We conducted a systematic review following the Preferred Reporting Items for Systematic Review 
and Meta-Analysis (PRISMA) guidelines [18]. A protocol for this review has been registered with 
PROSPERO (identifier: CRD42017076525).
Search strategy
We searched Medline, PsychINFO and EMBASE from 1 January 2000 to 27 September 2017 using 
keywords and MeSH terms related to substance use, healthcare utilisation and observational study 
designs (full terms included in the Supplementary Information). We also included studies from a 
manual search of references. On 3 December 2018 we updated our search using the same databases, 
search terms and inclusion criteria.
Study inclusion and exclusion criteria
We included English-language cohort and cross-sectional studies where 75% or more of participants 
recently used illicit drugs. Illicit drugs were defined as heroin, powder cocaine, crack cocaine, 
methamphetamine, amphetamine, ecstasy/MDMA, cannabis, hallucinogens, or novel psychoactive 
substances. We also included individuals who had a diagnosis of ‘substance use disorder’ or were 
recruited from drug treatment services, where we were able to determine that at least 75% used illicit 
drugs rather than alcohol only. Primary outcomes were the rate or cumulative incidence of ED 
episodes, hospital admissions and primary care presentation. We excluded studies of participants 
recruited from acute healthcare services (such as ED), who had acute disease (such as hepatitis A) 
who were pregnant, or were aged under 18. We also excluded studies with fewer than 30 participants 
or less than 30 days of observation per participant.
Study quality assessment
Methodological quality was assessed using a modified Newcastle-Ottowa scale [19] that included 
recruitment bias, non-response, ascertainment of illicit drug use, ascertainment of healthcare 
utilisation, adequacy of follow-up (for cohort studies), selection of comparison groups (for relative 
measures), and adjustment (for relative measures). Full details are given in Supplementary 
Information.
Screening and data extraction
Two authors (DL and JF) independently screened titles and abstracts using Rayyan [20]. There was 
agreement of 94% (Cohen’s Kappa 0.58) and conflicts were resolved through discussion. We 
accessed full texts and one author (DL, JF or EK) used a piloted data extraction tool to record details 
including the study design, year, location of the study, recruitment setting (drug treatment services, 
community or healthcare), participant demographics, predominant drugs used, and denominator and 
numerator for primary outcomes. Where relative frequencies (such as rate ratios) were reported, we 
also recorded the ratio and details of the comparison group. Where predictors of healthcare use and 
cause-specific healthcare use were reported, we marked the study for narrative synthesis. A second 
author checked that all data was accurate. Queries that could not be resolved were referred to KIM for 
a final decision.
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Analysis
In a narrative review, we described: (i) the range of values of the primary outcomes; (ii) predictors of 
healthcare utilisation; and (iii) causes of healthcare utilisation by disease.
In quantitative analysis, we displayed frequency rates of ED and inpatient utilisation using forest 
plots. To provide informal comparisons with the general population, we used published frequencies of 
healthcare utilisation in the US, Canada, Australia and the UK [21–23], for the general population 
group with the most similar age- and sex-profile as the study population. Details of the comparison 
group used for each study are given in the archived dataset.
We conducted random effects meta-analysis to report the average frequency of healthcare utilisation 
across study populations, limited to results from high-income countries and excluded studies of 
subgroups likely to have unusual healthcare utilisation (such as people living with HIV and prisoners). 
We anticipated that the strongest determinants of heterogeneity would be the predominant drug and 
the country where the study was conducted and therefore stratified results by these variables. As an 
exploratory analysis of further sources of heterogeneity (not pre-specified), we included each of the 
following variables in the meta-analysis equation as a moderator [24]: recruitment setting (healthcare, 
drug treatment services, community or prison), country, study design, study era (1990-1999, 2000-
2009, 2010-2018), risk-of-bias score (low or high), age (average age under or over 30) and sex 
(greater or less than 60% male), using a threshold of p<0.05 to identify significant moderators.
All analysis was conducted using R version 3.5.1.
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RESULTS
Search results
Our search identified 5,528 studies after deduplication, of which 313 were selected for full-text 
review and 92 were included. Figure 1 shows a flow-chart of studies. Some studies included groups 
from distinct regions or with distinct drug use patterns, while others duplicated samples from other 
studies, and we identified 98 unique populations with 204 relevant data points. The full dataset is 
available in Supplementary Information.
<< Figure 1 about here >>
Description of study populations
Of the 98 study populations: 53 were in the United States; 16 in Australia; 13 in Canada; 3 in Ireland; 
2 each in Taiwan, Italy, New Zealand, UK, Vietnam; and 1 each in Denmark, Finland and Norway.
Although the search strategy included people using any illicit drugs, studies focused on people who 
used illicit drugs associated with dependence. The largest group was people using opiate substitution 
(31 populations), mostly recruited from drug treatment services. The next largest was people who 
inject drugs (29 populations), mostly recruited from community settings. Eight studies focused on 
cannabis users, seven focused on stimulant users (where injecting was not specified) and five focused 
on opiate users (where injecting was not specified).  Figure 2 shows the number of study populations 
by predominant drug used and recruitment setting. No studies recruited participants who 
predominantly used MDMA/ecstasy, powder cocaine, novel psychoactive substances or hallucinogens 
such as LSD and psilocybin.
<< Figure 2 about here >>
A mean of 68% (sd. 12%) of participants were male and the mean of average ages (reported in some 
studies as means and in others as medians) was 36.7 (sd. 6.0).
Study quality
58/204 data points had high risk of bias. The main risk was lack of information on non-response. The 
overall risk of bias was not associated with frequency of healthcare utilisation in meta-analysis (see 
below). Table 1 summarises results from the quality assessment.
<< Table 1 about here  >>
Narrative review
Range of values
Frequencies of all outcomes were high and heterogeneous. ED utilisation ranged from 19 [25] to 
1,061 [26] per 100 person-years. The proportion of participants visiting ED in the past 12 months 
ranged from 10% [27] to 72% [28]. Studies including relative measures showed frequency of ED 
utilisation of 3-10 times that of comparison groups not using illicit drugs [29–32]. Exceptions were a 
study in rural Taiwan showing that people who inject heroin had a similar rate of ED presentation as 
the general population [33], and a study of older people who use cannabis in the United States 
showing similar odds of ED presentation as those who do not use cannabis [34].
The rate of inpatient episodes ranged from 8 [3] to 852 [29] per 100 person-years. The proportion of 
participants who were hospitalised in the past 12 months ranged from 8% [35] to 41% [36]. Studies 
Page 7 of 45 Addiction
For Review Only
Page 8 of 21
including relative measures showed frequency of hospital admission of 2-8 times that of comparison 
groups not using illicit drugs [29–31,37–40]. Again, studies of people who inject drugs in rural 
Taiwan and older people who use cannabis in the United States were exceptions, showing similar 
frequencies of hospital admission to the general population [33,41].
There were fewer studies primary care utilisation. Ten studies reported rates, ranging from 231 [42] to 
2,087 [37] episodes per 100 person-years. The proportion of participants visiting primary care in the 
past 12 months ranged from 38% [43] to 90% [44]. Three studies found higher frequency than the 
general population: a study of insurance data in Canada found people with diagnoses of ‘substance 
abuse’ had 4.2 times more primary care visits than those without this diagnosis [37]; a study of 
patients at a specialist primary care clinic in Ireland that found that those with methadone 
prescriptions had 4.2 times the odds of a primary care consultation during 6 months, excluding visits 
for drug-related problems [45]; and a study of people in drug treatment in Australia that found those 
primarily in treatment for opioids had a median of 12 primary care visits in the past year, compared to 
7 for those in treatment for alcohol [44]. Other studies found low absolute frequency of presentation 
without providing formal comparisons with the general population. For example, only 58% of people 
who inject drugs in Baltimore saw a primary care doctor over three years [46]; 53% of people who 
use methamphetamine in Australia saw a primary care doctor over 12 months [47]; and 32% of people 
who inject drugs in Montreal saw a primary care provider over six months, which was informally 
compared to 90% in the general population [48].
Studies investigating the frequency of healthcare utilisation in more than one setting showed that 
primary care episodes are more frequent than ED or inpatient episodes [49–53].
Predictors of healthcare utilisation
ED presentation was consistently associated with regular or recent injecting [54–57], sex work 
[54,58], diagnosed Hepatitis C [39], diagnosed HIV [31,36,56,59,60] , female sex [36,49,61–64] , 
homelessness or unstable housing [26,55,56,61,65], crack cocaine or stimulant use [56,61,62], alcohol 
use [63,66,67], polydrug use [47,68], and mental health problems [36,37,63].
Hospital admission was associated with similar factors: regular or recent injecting [55–57,69,70], 
diagnosed Hepatitis C [71,72], diagnosed HIV [35,56,69,70,73] , low CD4 count among HIV positive 
participants [74], female sex [38,39,49,69,70,72,74], homelessness or unstable housing [55,69] 
alcohol use [72], polydrug use [47], and mental health problems [31,37].
One study (the Melbourne Injecting Drug User Cohort Study) reported similar associations with 
primary care utilisation: regular injecting, homelessness, cocaine injection and unstable income 
[48,75]. 
Opiate substitution treatment was consistently associated with lower frequency of ED presentation 
and hospital admission [27,36,42,53,57,71,73,76–81] than comparison groups of untreated opiate 
users. Among substitution patients, consistent medication was associated with a lower rate of ED 
utilisation [77,78,82]. Some studies looked at different types of treatment. For example, one study 
found that take-home methadone was associated with lower risk of hospital admission [83]. No 
studies looked at the effect of treatment for dependence on drugs other than opiates.
Some studies reported non-significant associations with these factors, but none found effects in the 
opposite direction.
Although some studies show that mental or physical morbidity predicts healthcare utilisation, no 
studies attempted to show whether increased frequency of healthcare utilisation among people who 
use illicit drugs was explained by morbidity or other indicators of need for services.
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Causes of healthcare utilisation
Studies with cause-specific data showed that a minority of ED and inpatient episodes relate to the 
direct effects of illicit drugs, such as withdrawal, overdose and intoxication (Figure 3). Infections and 
particularly skin and soft tissue infections were common causes of ED and inpatient episodes in study 
populations in Canada [26,31,54,56,59,69], Norway [42] and Taiwan [33]. All infections and 
particularly pneumonias were important causes of healthcare utilisation in HIV positive opiate users 
[70,74]. Infections were less important causes of healthcare utilisation in Australia [84,85]. Traumas, 
injuries and mental health problems were important causes of ED utilisation and hospital admission in 
all countries [33,54,56,72,84,85]. 
<< Figure 3 about here >>
Quantitative analysis
We conducted meta-analysis of healthcare utilisation rates (25 studies reporting ED episodes and 25 
reporting hospital admission) and 12-month cumulative incidence (11 studies reporting ED episodes 
and 11 reporting hospital admission). 12 months was the most common period examined in the 
literature. While we collected data from studies of other periods, we did not analyse this data because 
the periods varied too widely. We were unable to determine the consistency of the definition of 
primary care visits across studies and therefore did not attempt quantitative analysis. We restricted the 
analysis to populations who primarily use heroin, crack cocaine or methamphetamine or have a 
diagnosis of ‘substance abuse disorder’ or drug dependence, since there were few studies of people 
who use cannabis or have other patterns of use.
ED frequencies are shown in figures 4 and 5. An average of 29% (95% CI 24%-35%) of participants 
visited ED over a 12-month period. The pooled rate was 151 visits per 100 person-years (95% CI 114-
201). There was high heterogeneity, with I2 approaching 100% for both analyses. 32 study populations 
were matched with published rates for groups of a similar age and sex in the general population. ED 
presentation ranged from 0.9 to 24.7 times the general population (mean 4.8). Stratified meta-analysis 
by predominant drug and country did not show significant differences to the overall pooled estimate 
(see Supplementary Information), and the exploratory meta-regression found no significant 
moderators.
<< Figures 4 and 5 about here >>
Hospital admission rates and cumulative incidences are shown in figures 4 and 5. An average of 22% 
(95% CI 15%-31%) of participants were hospitalised over a 12-month period. The pooled rate was 41 
episodes per 100 person-years (95% CI 30-57). There was high heterogeneity, with I2 approaching 
100% for both analyses. 27 study populations were matched with published rates for comparable 
groups in the general population. Hospital admission rates ranged from 1.9 to 35.5 times the general 
population (mean 7.1). As with the ED results, stratified meta-analysis by predominant drug and 
country did not show significant differences to the overall pooled estimate, and the exploratory meta-
regression found no significant moderators.
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DISCUSSION
To our knowledge this is the first systematic review of healthcare utilisation in people who use illicit 
drugs. The majority of available evidence relates to people who use heroin, methamphetamine and 
crack cocaine, or have a diagnosis of drug dependence. The results show high but widely varying 
frequency of ED presentation and hospital admission in this group.
The pooled frequencies of ED and hospital admissions are substantially higher than the general 
population. In part, this reflects morbidity and greater need for treatment. However, higher utilisation 
does not necessarily represent good healthcare access. A systematic review in 2009 [86] identified ten 
studies showing that people with substance use disorders are less likely to receive definitive treatment 
for specific conditions, despite higher all-cause attendance. For example, a study of veterans with 
diagnoses of diabetes in the US found that participants with comorbid substance use were less likely 
to receive foot or retina examinations [87]. Our finding of high utilisation of acute services may not 
represent good access, but a pattern where primary and preventative healthcare is poor and unplanned 
healthcare is common.
The results contrast with studies of healthcare among people who use alcohol, which find that 
drinkers (including heavy drinkers) have lower rates of healthcare utilisation than abstainers [88]. 
This is likely to be explained by abstention among people who are unwell, rather than a protective 
effect of alcohol. In contrast, this review found that people who use illicit drugs present to health 
services much more frequently than the general population. This may be because studies of people 
who use illicit drugs tend to focus on people who are dependent or use drugs associated with health 
harms, while studies of alcohol may include large numbers of more moderate drinkers.
Predictors of healthcare utilisation were consistent across studies, including unstable housing, drug 
injection, and mental health problems. These factors reflect previously identified risk factors for poor 
health outcomes in people who use drugs [89], and are likely to be associated with greater need for 
healthcare.
Effectively all of the variation across studies was due to differences between populations rather than 
within-study error. Despite consistent predictors of healthcare utilisation within studies, we were not 
able to explain the variation between studies by the predominant drugs used by study participants, the 
country of the study or any other study-level variables that we collected. Results varied widely even 
within countries and populations with apparently similar drug use. For example, in the United States, 
the rate of hospital admission of people in opiate substitution therapy ranged from 51 to 592 per 100 
person-years [53,76–78,90–92]. Other research has conceptualised access to health services as a 
product of individual factors, social contexts and healthcare systems [93,94]. The extent of the 
heterogeneity in our results is unlikely to be fully explained by individual factors that we did not 
capture. This suggests that social and healthcare contexts can substantially affect healthcare 
utilisation. The heterogeneity also highlights the difficulty of generalising results from single studies 
of healthcare utilisation.
The review identified three main gaps in the evidence. First, 84% of study populations were from the 
United States, Canada or Australia. We did not identify any studies from low income countries. 
Second, there were few studies with primary care data, even though existing studies suggest people 
who use illicit drugs visit primary care more often than acute healthcare settings [49–53], contrary to 
the stereotype of reliance on ED. Third, almost all studies were of people who use heroin, crack 
cocaine or methamphetamine, or have a diagnosis of drug dependence. There were only eight studies 
of people who use cannabis and none of people using MDMA/ecstasy, powder cocaine, 
hallucinogens, novel psychoactive substances or other drugs. 
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The results highlight the need for interventions that improve general health outcomes among people 
who use drugs. Despite a body of research into the effectiveness of opiate substitutes to reduce use of 
street heroin [95], community-distributed naloxone to prevent overdose deaths [96], strategies to 
reduce transmission of hepatitis C and improve access to hepatitis C treatment [97], and some 
strategies to improve treatment of soft tissue infections among people who inject drugs [98], there is 
limited research into interventions that can improve treatment of health problems that are not 
specifically associated with drug use. Some studies have shown that Housing First can reduce all-
cause ED utilisation, though study outcomes tend to focus on substance use rather than broader health 
[99]. Case management (where a single case manager is assigned to each patient) can improve drug 
treatment outcomes, but again evidence of the effect on broader health outcomes is limited [100].
Limitations of the evidence
Most studies in the past have described patients in healthcare services to show the proportion that use 
drugs, rather than using population-based approaches. This has led in particular to a focus on ED and 
‘frequent fliers’. To broaden this focus, we synthesised observational studies that often report 
healthcare utilisation as a secondary outcome. The strength of this approach is that it has shown the 
wide variation in utilisation of acute hospital services, and in some settings primary care may be 
attended more frequently. The limitation is that many studies provide limited insight into predictors 
and patterns of utilisation.
Half the studies in the review (43/92) rely on linked electronic healthcare records, which may have 
inaccuracies in diagnostic coding. For example, there is evidence that drug-related events such as 
overdoses are under-recorded in ED data and may be given other diagnostic codes [101,102]. This 
could contribute to the small proportion of healthcare episodes that are ‘drug-related’ in our results. In 
addition, few studies include data from the recent period when synthetic opioids such as fentanyl 
became more common in North American illicit drug markets. Opioid-related overdoses in the US 
have increased during this period [103], and the proportion of healthcare episodes that are drug-
related may have increased.
The quality assessment identified non-response as the most common problem. This usually resulted 
from recruitment relying on volunteers or convenience samples rather than a systematic or random 
approach. These methods are often necessary, since it can be difficult to construct sample frames of 
people who use drugs. Difficulties in constructing sample frames may also account for the relative 
lack of studies of people using some illicit drugs, such as powder cocaine, though this may also be 
due to less severe health outcomes in these groups.
None of the studies included in this review looked at whether higher morbidity explained higher rates 
of healthcare use, so we were not able to discuss the appropriateness of health service use.
Limitations of the review and meta-analysis
First, we only included English-language studies, which may partially explain the large proportion of 
studies from English speaking countries – though the English-language restriction only removed 
179/5,528 search results. Second, given the heterogeneity of results, meta-analysis is only intended to 
provide an average across studies rather than a meaningful estimate of healthcare utilisation for any 
specific population. Third, we defined healthcare utilisation with simple rates or proportions. While 
this enabled us to perform a traditional systematic review, it meant that the results provide limited 
insight into the appropriateness or equity of the high rates of healthcare utilisation that we observed. 
Finally, our review focused on three mainstream healthcare settings (primary care, ED and inpatient 
hospital care), and did not consider other potential sources of healthcare such as community drug 
treatment services, which sometimes provide a wider set of interventions. Future research should 
Page 11 of 45 Addiction
   
Page 12 of 21
consider the full range of healthcare provision for people who use drugs, including opportunities for 
integration between drug treatment and mainstream health services.
Conclusion
People who use illicit drugs present to acute health services several times more often than comparison 
groups, across primary care, ED and inpatient settings, reflecting high morbidity. Utilisation rates are 
highest in those who inject drugs, homeless people and those with mental health problems. Research 
is needed into the quality of healthcare for people who use illicit drugs, provision of healthcare in 
non-acute settings, and development of health services that are considered safe and acceptable to this 
group.
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FIGURES AND TABLES WITH LEGENDS





Recruitment bias 204 28 14%
Non-response 204 121 59%
Ascertainment of illict drug use 204 43 21%
Ascertainment of healthcare utilisation 204 44 22%
Adequacy of follow-up 82 21 26%
Selection of comparison group 47 4 9%
Adjustment for confounders 47 4 9%
Global assessment 204 58 28%
Figure 1: Flow chart of included studies
Figure 2: Unique study populations by predominant drug and recruitment source
Figure 3: Main reason for healthcare utilisation
Figure 4: Forest plot of rates of healthcare utilisation. Studies in grey and italics are not included in 
the pooled estimate
Figure 5: Forest plot of 12-month cumulative incidence of healthcare utilisation. Studies in grey and 
italics are not included in the pooled estimate
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Figure 4: Forest plot of rates of healthcare utilisation. Studies in grey and italics are not included in the 
pooled estimate 
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Figure 5: Forest plot of 12-month cumulative incidence of healthcare utilisation. Studies in grey and italics 
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1 Search terms 
Medline 
1 addict*.mp 
2 (chemical adj2 dependenc*).mp 
3 (substance adj2 misuse*).mp 
4 (substance adj2 abus*).mp 
5 substance use.mp 
6 drug adj1 user*.mp 
7 (drug adj2 abus*).mp 
8 (drug adj2 dependen*).mp 











20 Substance-Related Disorders/ 
21 Amphetamine-Related Disorders/ 
22 Cocaine-Related Disorders/ 
23 Heroin Dependence/ 
24 Substance Abuse, Intravenous/ 
25 Cannabis/ 
26 Marijuana abuse/ 
27 Heroin/ 






34 healthcare use.mp 
35 healthcare usage.mp 
36 care use.mp 
37 care usage.mp 
38 service use.mp 
39 service usage.mp 
40 (hospital* adj3 rate*).mp 
41 (hospital* adj3 incidence).mp 
42 (hospital* adj3 prevalence).mp 
43 ("use of" adj2 primary).mp 
44 ("use of" adj2 secondary).mp 
45 ("use of" adj2 emergency).mp 
46 ("use of" adj2 service*).mp 
47 ("use of" adj2 healthcare).mp 
48 ("use of" adj2 care).mp 
49 (utili* adj2 primary).mp 
50 (utili* adj2 secondary).mp 
51 (utili* adj2 emergency).mp 
52 (utili* adj2 service*).mp 
53 (utili* adj2 healthcare).mp 
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54 (utili* adj2 care).mp 
55 (visits adj2 primary).mp 
56 (visits adj2 secondary).mp 
57 (visits adj2 emergency).mp 
58 (visits adj2 service*).mp 
59 (visits adj2 healthcare).mp 
60 (visits adj2 care).mp 
61 Health Resources/ 
62 Health Expenditures/ 
63 Primary Health Care/ 
64 Secondary Care/ 
65 or/34-64 
66 Epidemiologic studies/ 
67 exp cohort studies/ 
68 (cohort adj1 stud*).tw. 
69 (cohort adj1 analy*).tw. 
70 ("follow up" adj1 stud*).tw 




75 Cross-sectional studies/ 




80 33 and 65 
81 79 and 80 
82 limit 81 to (english language and yr="2000 -Current") 
Embase 
1 addict*.mp 
2 (chemical adj2 dependenc*).mp 
3 (substance adj2 misuse*).mp 
4 (substance adj2 abus*).mp 
5 substance use.mp 
6 drug adj1 user*.mp 
7 (drug adj2 abus*).mp 
8 (drug adj2 dependen*).mp 












21 drug dependence/ 
22 amphetamine dependence/ 
23 cannabis addiction/ 
24 opiate addiction/ 
25 cocaine dependence/ 
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26 methamphetamine dependence/ 
27 heroin dependence/ 







35 healthcare use.mp 
36 healthcare usage.mp 
37 care use.mp 
38 care usage.mp 
39 service use.mp 
40 service usage.mp 
41 (hospital* adj3 rate*).mp 
42 (hospital* adj3 incidence).mp 
43 (hospital* adj3 prevalence).mp 
44 ("use of" adj2 primary).mp 
45 ("use of" adj2 secondary).mp 
46 ("use of" adj2 emergency).mp 
47 ("use of" adj2 service*).mp 
48 ("use of" adj2 healthcare).mp 
49 ("use of" adj2 care).mp 
50 (utili* adj2 primary).mp 
51 (utili* adj2 secondary).mp 
52 (utili* adj2 emergency).mp 
53 (utili* adj2 service*).mp 
54 (utili* adj2 healthcare).mp 
55 (utili* adj2 care).mp 
56 (visits adj2 primary).mp 
57 (visits adj2 secondary).mp 
58 (visits adj2 emergency).mp 
59 (visits adj2 service*).mp 
60 (visits adj2 healthcare).mp 
61 (visits adj2 care).mp 
62 hospital utilization/ 
63 health care utilization/ 
64 or/35-63 
65 Longitudinal study/ 
66 Retrospective study/ 
67 Randomized controlled trials/ 
68 66 not 67 
69 Cohort analysis/ 
70 (cohort adj1 stud*).mp 
71 ("follow up" adj1 stud*).tw 
72 (observational adj1 stud*).tw. 







80 34 and 64 
81 79 and 80 
82 limit 81 to (english language and yr="2000 -Current") 
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PsychINFO 
1 addict*.mp 
2 (chemical adj2 dependenc*).mp 
3 (substance adj2 misuse*).mp 
4 (substance adj2 abus*).mp 
5 substance use.mp 
6 drug adj1 user*.mp 
7 (drug adj2 abus*).mp 
8 (drug adj2 dependen*).mp 












21 Drug Abuse/ 
22 Drug Dependency/ 
23 Drug Addiction/ 
24 Substance Use Disorder/ 










35 healthcare use.mp 
36 healthcare usage.mp 
37 care use.mp 
38 care usage.mp 
39 service use.mp 
40 service usage.mp 
41 (hospital* adj3 rate*).mp 
42 (hospital* adj3 incidence).mp 
43 (hospital* adj3 prevalence).mp 
44 ("use of" adj2 primary).mp 
45 ("use of" adj2 secondary).mp 
46 ("use of" adj2 emergency).mp 
47 ("use of" adj2 service*).mp 
48 ("use of" adj2 healthcare).mp 
49 ("use of" adj2 care).mp 
50 (utili* adj2 primary).mp 
51 (utili* adj2 secondary).mp 
52 (utili* adj2 emergency).mp 
53 (utili* adj2 service*).mp 
54 (utili* adj2 healthcare).mp 
55 (utili* adj2 care).mp 
56 (visits adj2 primary).mp 
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57 (visits adj2 secondary).mp 
58 (visits adj2 emergency).mp 
59 (visits adj2 service*).mp 
60 (visits adj2 healthcare).mp 
61 (visits adj2 care).mp 
62 Primary Health Care 
63 Health Care utilization 
64 or/35-63 
65 Longitudinal Studies/ 
66 Followup Studies/ 
67 Retrospective Studies/ 
68 Cohort analysis/ 
69 (cohort adj1 stud*).tw. 
70 ("follow up" adj1 stud*).tw. 
71 (observational adj1 stud*).tw. 
72 (epidemiologic* adj1 stud*).tw. 
73 Longitudinal.tw. 
74 Retrospective.tw. 





80 34 and 64 
81 79 and 80 
82 limit 80 to (english language and yr="2000 -Current") 
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2 Modified Newcastle-Ottowa scale 
Representativeness of people who use illicit drugs 
Good representativeness of target population (e.g. random sampling, complete sample) 1 
Selection process does not ensure representativeness (e.g. snowball sampling, systematic 
sample), but is clearly described and is unlikely to select low or high healthcare users 
1 
Selection process likely to select low or high healthcare users 0 
No description of the derivation of sample or unclear 0 
Non-response  
Comparability between respondents and non-respondents was established and/or response 
rate >=70% 
1 
The comparability between respondents and non-respondents was unsatisfactory and response 
rate <70% (or not specified) 
0 
No statement or unclear 0 
Ascertainment of illicit drug use 
From structured interview or medical records: clear description of drugs used 1 
From structured interview or medical records: partial description of drugs used 1 
Not directly ascertained (e.g. relying drug-related sampling locations) 0 
No statement or unclear 0 
Ascertainment of healthcare use 
Record linkage 1 
Self report: questions described and consistently applied 1 
Self report: questions not described or not consistently applied 0 
No statement or unclear 0 
Adequacy of follow-up (cohorts only) 
Complete follow up - all subjects accounted for 1 
Subjects lost to follow up unlikely to introduce bias - small number lost (>=80% follow up) 
or description provided of those lost showing they are similar 
1 
Follow up rate < 80% and no description of those lost (or description shows they are 
substantially different) 
0 
No statement or unclear 0 
Selection of the comparison group (studies with comparative measures (e.g. rate ratios, 
prevalence ratios) 
Drawn from the same population that people who use drugs are drawn from 1 
Drawn from a different source 0 
No statement or unclear 0 
Comparability of groups on the basis of design or analysis (studies with comparative 
measures (e.g. rate ratios, prevalence ratios) 
Study controls for a number of confounders, including the most important (likely to be age) 1 
Study controls for the most important confounder only 1 
Study controls for confounders, but not the most important one 0 
No control for differences between groups 0 
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Determining overall risk of bias 
Maximum points 
available 
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3 Full list of included studies 
First author Title Year Journal Volume Issue 
French Chronic illicit drug use, health services utilization 
and the cost of medical care 
2000 Soc Sci Med 50 0 
Wall Social costs of untreated opioid dependence 2000 Journal of urban 
health 
77 4 
Knowlton Access to medical care and service utilization 
among injection drug users with HIV/AIDS 
2001 Drug Alcohol Depend 64 0 
Laine Regular outpatient medical and drug abuse care 
and subsequent hospitalization of persons who use 
illicit drugs 




Palepu Hospital utilization and costs in a cohort of 
injection drug users. 
2001 CMAJ 165 4 
Pollack The impact of needle exchange-based health 
services on emergency department use 
2002 Journal of General 
Internal Medicine 
17 5 
Riley Health services utilization by injection drug users 
participating in a needle exchange program 
2002  Am J Drug Alco- hol 
Abuse 
28 3 
Schoenbaum Predictors of hospitalization for HIV-positive 
women and men drug users, 1996-2000. 
2002 Public health reports 117 NA 
Darke Health service utilization and benzodiazepine use 
among heroin users: Findings from the Australian 
Treatment Outcome Study (ATOS) 
2003 Addiction 98 8 
Floris-Moore Gender and hospitalization patterns among HIV-
infected drug users before and after the 
availability of highly active antiretroviral therapy. 




Juday The role of Medicaid HMO enrollment in the 
longitudinal utilization of medical care services in 
a cohort of injecting drug users in Baltimore, 
Maryland. 
2003 Substance Abuse 24 1 
Reynolds Use of emergency room services by out-of-
treatment drug users in Long Beach, California 
2003 Journal of Addictive 
Diseases 
22 2 
Robles Determinants of health care use among Puerto 
Rican drug users in Puerto Rico and New York 
City. 
2003 Clinical infectious 
diseases 
37 12 
Stein Injection frequency mediates health service use 
among persons with a history of drug injection 
2003 Drug and Alcohol 
Dependence 
70 2 
Turner Effects of long-term, medically supervised, drug-
free treatment and methadone maintenance 
treatment on drug users<U+0092>  mergency 
department use and hospitalization 
2003 Clinical Infectious 
Diseases 
37 S5 
Wang Mortality in HIV-seropositive versus -
seronegative persons in the era of highly active 
antiretroviral therapy: implications for when to 
initiate therapy. 
2004 The Journal of 
infectious diseases 
190 6 
Kelly Health service utilisation among regular 
methamphetamine users 
2005 NDARC Technical 
Report 
NA 0 
Kerr High rates of primary care and emergency 
department use among injection drug users in 
Vancouver 
2005 Journal of Public 
Health 
27 1 
Lundgren Factors associated with emergency room use 
among injection drug users of African-American, 
Hispanic and White-European background 
2005 Am J Addict 14 3 
Mills Post-traumatic stress disorder among people with 
heroin dependence in the Australian treatment 
outcome study (ATOS): prevalence and correlates. 
2005 Drug and Alcohol 
Dependence 
77 3 
Friedmann Do Mechanisms that Link Addiction Treatment 
Patients to Primary Care Influence Subsequent 
Utilization of Emergency and Hospital Care? 
2006 Medical care 44 1 
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First author Title Year Journal Volume Issue 
Leukefeld A prospective examination of high-cost health 
services utilization among drug using prisoners 
reentering the community. 
2006 The journal of 
behavioral health 
services & research 
33 1 
Martinez Impact of Permanent Supportive Housing on the 
Use of Acute Care Health Services by Homeless 
Adults. 
2006 Psychiatric Services 57 7 
Siegal Emergency department utilization by crack-
cocaine smokers in dayton, ohio 
2006 Am J Drug Alcohol 
Abuse 
32 1 
Darke Changes in the use of medical services and 
prescription drugs amongst heroin users over two 
years 
2007 Drug Alcohol Rev 26 0 
Federman Primary care affiliations of adults in a methadone 
program with onsite care 
2007 Journal of Addictive 
Diseases 
26 1 
Gourevitch On-site medical care in methadone maintenance: 
associations with health care use and expenditures. 
2007 Journal of substance 
abuse treatment 
32 2 
Baum Quality of life, symptomatology and healthcare 
utilization in HIV/HCV co-infected drug users in 
Miami. 
2008 Journal of addictive 
diseases 
27 2 
Burnette Prevalence and health correlates of prostitution 
among patients entering treatment for substance 
use disorders. 
2008 Archives of General 
Psychiatry 
65 3 
Ngo Comparing drug-related hospital morbidity 
following heroin dependence treatment with 
methadone maintenance or naltrexone 
implantation. 
2008 Archives of General 
Psychiatry 
65 4 
Skeie Somatic health among heroin addicts before and 
during opioid maintenance treatment: A 
retrospective cohort study 
2008 BMC Public Health 8 NA 
Benjamin-
Johnson 
Access to medical care, use of preventive services, 
and chronic conditions among adults in substance 
abuse treatment 
2009 Psychiatric Services 60 12 
Cullen Chronic illness and multimorbidity among 
problem drug users: A comparative cross sectional 
pilot study in primary care 
2009 BMC family practice 10 NA 
Ryder Prevalence of problem alcohol use among patients 
attending primary care for methadone treatment 
2009 BMC family practice 10 NA 
Hartzler Dissolution of a harm reduction track for opiate 
agonist treatment: Longitudinal impact on 
treatment retention, substance use and service 
utilization. 
2010 International Journal 
of Drug Policy 
21 1 
Lloyd-Smith Determinants of hospitalization for a cutaneous 
injection-related infection among injection drug 
users: a cohort study 
2010 BMC public health 10 NA 
McCarty Methadone maintenance and the cost and 
utilization of health care among individ- uals 
dependent on opioids in a commercial health plan 
2010 Drug and Alcohol 
Dependence 
0 0 
Robbins Health and oral health care needs and health care-
seeking behavior among homeless injection drug 
users in San Francisco. 
2010 Journal of urban 
health 
87 6 
Baser Cost and utilization outcomes of opioid-
dependence treatments 
2011 The American journal 
of managed care 
17 NA 
Schmidt The impact of substance use disorders on the 
course of schizophrenia-A 15-year follow-up 




Fairbairn Emergency department utilization among a cohort 
of HIV-positive injecting drug users in a Canadian 
setting 
2012 The Journal of 
emergency medicine 
43 2 
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First author Title Year Journal Volume Issue 
Marshall Frequent methamphetamine injection predicts 
emergency department utilization among street-
involved youth. 
2012 Public Health 126 1 
Schwarz Retention on buprenorphine treatment reduces 
emergency department utilization, but not 
hospitalization, among treatment-seeking patients 
with opioid dependence. 
2012 Journal of substance 
abuse treatment 
43 4 
Walley Methadone dose, take home status, and hospital 
admission among methadone maintenance 
patients. 
2012 Journal of Addiction 
Medicine 
6 3 
Aitken A cross-sectional study of emergency department 
visits by people who inject drugs 
2013 Emergency medicine 
journal 
30 5 
Chen Health care service utilization and associated 
factors among heroin users in Northern Taiwan. 
2013 Addictive Behaviors 38 11 
Dietze The relationship between alcohol use and injecting 
drug use: Impacts on health, crime and wellbeing 
2013 Drug and Alcohol 
Dependence 
128 1 
Horyniak Establishing the Melbourne Injecting Drug User 
Cohort Study (MIX): Rationale, methods, and 
baseline and twelve-month follow-up results. 
2013 Harm Reduction 
Journal 
10 1 
Mark Psychiatric and medical comorbidities, associated 
pain, and health care utilization of patients 
prescribed buprenorphine. 
2013 Journal of substance 
abuse treatment 
44 5 
Merrall A record linkage study of hospital episodes for 
drug treatment clients in Scotland, 1996-2006. 
2013 Addiction Research & 
Theory 
21 1 
Cederbaum Utilization of emergency and hospital services 
among individuals in substance abuse treatment. 





Clay Persistence and healthcare utilization associated 
with the use of buprenorphine/naloxone film and 
tablet formulation therapy in adults with opioid 
dependence 
2014 Journal of Medical 
Economics 
17 9 
Fuster No detectable association between frequency of 
marijuana use and health or healthcare utilization 
among primary care patients who screen positive 
for drug use. 
2014 Journal of General 
Internal Medicine 
29 1 
Lynch Costs of care for persons with opioid dependence 
in commercial integrated health systems. 
2014 Addiction science & 
clinical practice 
9 NA 
Morasco Comparison of health service use among veterans 
with methamphetamine versus alcohol use 
disorders. 
2014 Journal of addiction 
medicine 
8 1 
Nambiar A cross-sectional study describing factors 
associated with utilisation of GP services by a 
cohort of people who inject drugs 
2014 BMC health services 
research 
14 NA 
Ngamini-Ngui High users of emergency departments in quebec 
among patients with both schizophrenia and a 
substance use disorder 
2014 Psychiatric Services 65 11 
Artenie Visits to primary care physicians among persons 
who inject drugs at high risk of hepatitis C virus 
infection: Room for improvement 
2015 Journal of Viral 
Hepatitis 
22 10 
Chen Health service utilization of heroin abusers: A 
retrospective cohort study 
2015 Addictive Behaviors 45 NA 
Darke Health Service Utilization among Heroin Users: 
11-Year Follow-up of the Australian Treatment
Outcome Study Cohort
2015 Addictive Disorders 
and their Treatment 
14 3 
Krupski Clinical needs of patients with problem drug use 2015 Journal of the 
American Board of 
Family Medicine 
28 5 
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Nambiar Mortality in the Melbourne injecting drug user 
cohort study (MIX) 
2015 Harm Reduction 
Journal 
12 1 
O'Brien Health, perceived quality of life and health 
services use among homeless illicit drug users. 
2015 Drug and alcohol 
dependence 
154 NA 
Onyeka Hospitalization in a cohort seeking treatment for 
illicit drug use in finland 
2015 Journal of Substance 
Abuse Treatment 
53 NA 
Pavarin Health status of users of the Bologna local health 
authority drug addiction treatment services: a 
study of hospital admissions in the period 2004-
2013. 
2015 Le infezioni in 
medicina 
23 1 
White Drugs-related death soon after hospital- discharge 
among drug treatment clients in Scotland: Record 
linkage, validation, and investigation of risk-
factors 
2015 PLoS ONE 10 11 
Whittaker Multiply disadvantaged: Health and service 
utilisation factors faced by homeless injecting 
drug consumers in Australia 
2015 Drug and Alcohol 
Review 
34 4 
Bhandari Marijuana users do not have increased healthcare 
utilization: A National Health and Nutrition 
Examination Survey (NHANES) study 
2016 European Journal of 
Internal Medicine 
34 NA 
Huynh Factors Influencing the Frequency of Emergency 
Department Utilization by Individuals with 
Substance Use Disorders 
2016 Psychiatric Quarterly 87 4 
Lintzeris Substance use, health status and service utilisation 
of older clients attending specialist drug and 
alcohol services 
2016 Drug and Alcohol 
Review 
35 2 
Lo-Ciganic Association between trajectories of buprenorphine 
treatment and emergency department and in-
patient utilization. 
2016 Addiction 111 5 
Lubman Characteristics of individuals presenting to 
treatment for primary alcohol problems versus 
other drug problems in the Australian patient 
pathways study 
2016 BMC Psychiatry 16 1 
Mohlman Impact of Medication-Assisted Treatment for 
Opioid Addiction on Medicaid Expenditures and 
Health Services Utilization Rates in Vermont 
2016 Journal of Substance 
Abuse Treatment 
67 NA 
Tran Economic vulnerability of methadone 
maintenance patients: Implications for policies on 
co-payment services 
2016 International Journal 
of Drug Policy 
31 NA 
Wilkins An exploratory study of the health harms and 
utilisation of health services of frequent legal high 
users under the interim regulated legal high 
market in central Auckland 
2016 New Zealand Medical 
Journal 
129 1431 
Campbell The role of marijuana use disorder in predicting 
emergency department and inpatient encounters: 
A retrospective cohort study 
2017 Drug and Alcohol 
Dependence 
178 NA 
Choi Older adults' marijuana use, injuries, and 
emergency department visits 
2017 American Journal of 
Drug and Alcohol 
Abuse 
NA NA 
Cucciare Longitudinal associations between outpatient 
medical care use and substance use among rural 
stimulant users 
2017 American Journal of 
Drug and Alcohol 
Abuse 
NA NA 
Decker Long-term outcomes after residential substance 
use treatment: Relapse, morbidity, and mortality. 
2017 Military Medicine 182 1 
Graham How Much Do Mental Health and Substance 
Use/Addiction Affect Use of General Medical 
Services? Extent of Use, Reason for Use, and 
Associated Costs 
2017 Canadian Journal of 
Psychiatry 
62 1 
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Kendall A cohort study examining emergency department 
visits and hospital admissions among people who 
use drugs in Ottawa, Canada 
2017 Harm Reduction 
Journal 
14 1 
Nambiar A prospective cohort study of hospital separations 
among people who inject drugs in Australia: 
2008<U+0096>2013 
2017 BMJ Open 7 8 
Nambiar Frequent emergency department presentations 
among people who inject drugs: A record linkage 
study 
2017 International Journal 
of Drug Policy 
44 NA 
Nguyen Quality of life and healthcare service utilization 
among methadone maintenance patients in a 
mountainous area of Northern Vietnam. 
2017 Health and Quality of 
Life Outcomes 
15 1 
Bahorik Alcohol, marijuana, and opioid use disorders: 5-
Year patterns and characteristics of emergency 
department encounters. 
2018 Substance abuse 0 0 
Beaulieu Major depressive disorder and access to health 
services among people who use illicit drugs in 
Vancouver, Canada. [References]. 





Choi Impact of depression and recreational drug use on 
emergency department encounters and hospital 
admissions among people living with HIV in 
Ontario: A secondary analysis using the OHTN 
cohort study. 
2018 PLoS ONE 0 0 
Han Marijuana use by middle-aged and older adults in 
the United States, 2015-2016.[Erratum appears in 
Drug Alcohol Depend. 2018 Sep 25;192:171; 
PMID: 30266000] 
2018 Drug & Alcohol 
Dependence 
0 0 
Manhapra Three-year retention in buprenorphine treatment 
for opioid use disorder among privately insured 
adults. 
2018 Psychiatric Services 0 0 
Robertson Associations between pharmacotherapy for opioid 
dependence and clinical and criminal justice 
outcomes among adults with co-occurring serious 
mental illness. 
2018 Journal of Substance 
Abuse Treatment 
0 0 
Shah Healthcare utilization and costs associated with 
treatment for opioid dependence. 
2018 Journal of Medical 
Economics 
0 0 
Shcherbakova Treatment Persistence Among Insured Patients 
Newly Starting Buprenorphine/Naloxone for 
Opioid Use Disorder. 
2018 Annals of 
Pharmacotherapy 
0 0 
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4 Stratified forest plots 
ED rates by predominant drug 
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ED rates by country 
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Inpatient rates by predominant drug 
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Inpatient rates by country 
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5 PRISMA checklist 








2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
p2 
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is 
already known.  
p3 
Objectives 4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 





5 Indicate if a review protocol exists, if and where it can be accessed 
(e.g., Web address), and, if available, provide registration 




6 Specify study characteristics (e.g., PICOS, length of follow-up) 
and report characteristics (e.g., years considered, language, 





7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
p4 
Search 8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.  
Suppl. Info. 
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, 





10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
p4 
Data items 11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and simplifications 
made.  
p4 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in 




13 State the principal summary measures (e.g., risk ratio, difference 




14 Describe the methods of handling data and combining results of 
studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
p5 
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
p4 
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16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.  
p5 
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each stage, 





18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and provide 
the citations.  
Suppl. Info. 
Risk of bias 
within studies 
19 Present data on risk of bias of each study and, if available, any 





20 For all outcomes considered (benefits or harms), present, for each 
study: (a) simple summary data for each intervention group (b) 





21 Present results of each meta-analysis done, including confidence 
intervals and measures of consistency.  
p8 
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across studies (see 





23 Give results of additional analyses, if done (e.g., sensitivity or 





24 Summarize the main findings including the strength of evidence 
for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
p9 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), 
and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
p10 
Conclusions 26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
pp10-11 
FUNDING 
Funding 27 Describe sources of funding for the systematic review and other 
support (e.g., supply of data); role of funders for the systematic 
review.  
p1 
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